On Sept. 4 the FDA posted a new and revised version of the following Import Alert on the detention without physical examination of:
On Sept. 3 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Sept. 2 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
FDA has issued its weekly Enforcement Report for Sept. 2, listing the status of recalls and field corrections for food, cosmetics, tobacco products, drugs, biologics and devices. The report covers both domestic and foreign firms.
On Sept. 1 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Aug. 31 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Aug. 28 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Aug. 27 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Aug. 26 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The FDA recently released a new guidance document responding to frequently asked questions about “regulatory and policy issues related to inspections, pending drug applications, and changes in manufacturing facilities for approved pharmaceutical products” during the COVID-19 pandemic. The guidance includes information on the impact of COVID-19 and related travel restrictions on inspections of drug facilities, FDA actions to address imports, and changes to drug applications in response to supply chain disruptions due to the pandemic.